 |
Research and Clinical Trials
UCLA Division of Rheumatology conducts cutting-edge biomedical and health-related research studies that include both interventional and observational studies. Our clinical studies are sponsored/funded by National Institute of Health (NIH), pharmaceutical companies, and/or non-profit medical institutions/organizations.
Treatment/Interventional studies are those in which the research subjects are assigned to a treatment or intervention and their outcomes are measured.
Observational studies are those in which individuals are observed and their outcomes are measured by the study investigators.
Current Clinical Trials
Rheumatoid Arthritis
Cholesterol
Lupus
Scleroderma
If you would like to get more information on any studies please call us at (310) 825-0096 or email rheumresearch@mednet.ucla.edu.
If you are interested in finding out more information of a particular study, please contact the study personnel.
|
Study Type |
Title of Study |
|
| Observational | Biomarkers in Rheumatoid Arthritis (Investigatory) Status: Recruiting |
Principal Investigator For more information, contact |
| Treatment |
A3921024: A Long Term, Open Label, Follow Up Study of Tafocitinib (CP 690,550) For Treatment of Rheumatoid Arthritis Status: Recruiting |
Principal Investigator
|
| Treatment |
Musculoskeletal Ultrasound as a Marker of Therapeutic Response to Abatacept in Rheumatoid Arthritis. 1 year study Status: Recruiting |
Principal Investigator Veena Ranganath, MD
|
| Treatment/ Interventional |
*Multiple studies |
Principal Investigators |
| Cholesterol | ||
| Observational | HDL Function in Patients With and Without Rheumatic Disease (Investigatory) |
Principal Investigators Christina Charles-Schoeman, MD For more information contact, 310-825-0096 |
| Lupus | ||
| Observational | Influence of DMARD Therapies for SLE on Levels of Pro-Inflammatory HDL Status: Recruiting | Principal Investigator Bevra Hahn, MD For more information contact |
| Treatment |
Epratuzumab vs Placebo- Phase 3 trial. Epratuzumab is a humanized monoclonal antibody of IgG class which specifically binds to CD22. Status: Recruiting |
Principal Investigators For more information contact |
| Treatment |
Illuminate-LY2127399 vs Placebo Phase 3 trial. LY2127399 is a human immunoglobulin G subclass 4-variant monoclonal antibody that neutralizes BAFF (like a subcutaneuos version of belimumab). Status: Recruiting |
Principal Investigators Jennifer Grossman, MD Maureen McMahon, MD For more information contact |
| Treatment | PF-04236921 vs Placebo
Phase 2 study. PF-04236921 is a fully human antibody of the immunoglobulin G that binds to IL-6. Status: Recruiting |
Principal Investigators For more information contact |
| Treatment |
MEDI-545 vs Placebo Phase 2 study. Medi-546 is a human immunoglobulin G1 kappa directed against Interferon alpha. Status: Recruiting |
Principal Investigators For more information contact |
| Observational | Lupus Genetics Status: Recruiting |
Principal Investigator 310-825-2230
|
| Observational | Biomarkers in Lupus Status: Recruiting |
Principal Investigator Ram Raj Singh, MD For more information contact Ram Raj Singh, MD |
| Observational | The Role of Gender Factors in Lupus and Autoimmunity Status: Recruiting |
Principal Investigator Ram Raj Singh, MD For more information contact |
| Observational | Autoimmunity Characteristics in Patients with Systemic Lupus Erythematosus versus Health Controals
Status: Recruiting |
Principal Investigator Jennifer King, MD For more information contact |
| Observational | Observational, Mechanisms of Inflammation and Immune Response in Skin Dermatoses.
Status: Recruiting |
Principal Investigator Jennifer King, MD For more information contact |
| Treatment/ Interventional |
*Multiple studies Status: Recruiting |
Principal Investigators Jennifer Grossman, MD; Maureen McMahon, MD |
| Scleroderma | ||
| Treatment/ Interventional |
*Multiple studies |
Principal Investigator For more information contact
|
| Treatment |
DUAL-1: Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of macitentan in patients with ischemic digital ulcers associated with systemic sclerosis Status: Recruiting |
Principal Investigators For more information contact
|
| Treatment |
WA27788: A PHASE II/III, MULTICENTER, RANDOMIZED, Status: Recruiting
|
Principal Investigator For more information contact |
| Treatment |
SLSII: Mycophenolate vs Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease Status: Recruiting |
Principal Investigator
|
| Other |
GWAS: Two Stage Genome-Wide Association Study in Systemic Sclerosis Status: Recruiting
|
Principal Investigators For more information contact |
| Other |
PHAROS: Outcome Studies in Systemic Sclerosis: A Prospective Database of Echocardiograms and PFTs on Patients with Limited Scleroderma (Standard of Care) Status: Recruiting
|
Principal Investigators For more information contact |
